We recently published a list of 15 Best Stocks to Buy According to Jim Simons’ Renaissance Technologies In this article, we are going to take a look at where United Therapeutics Corporation (NASDAQ:UTHR) stands against other best stocks to buy according to Jim Simons’ Renaissance Technologies.
Even after his passing in 2024, billionaire investor and mathematician Jim Simons remains known as the “Quant King” of hedge funds due to the extraordinary success of Renaissance Technologies, his quantitative trading firm based in New York. After years of researching the finance industry, Simons realized the untapped potential of employing quantitative analysis to capitalize on market inefficiencies. This insight led him to develop a data-driven investment strategy of analyzing market behavior solely using statistical and mathematical models. By identifying subtle, non-random patterns in financial data, the quant genius predicted future stock movements and generated impressive returns.
Although it is closed to outside investors, Jim Simons’ secretive Medallion hedge fund, a flagship of Renaissance, has produced ground-breaking results since its inception. The Medallion Fund raked in impressive returns of 56.6% and 74.6% during the early 2000s dot-com crash and the global financial crisis between 2007 and 2011. The fund has maintained a substantial annual return of 31.5% since its first two years of operation. At the time of his death, Simons was worth $31.4 billion, ranking him among the world’s wealthiest individuals, thanks to the strong market performance of the Medallion Fund and Renaissance.
Renaissance Technologies’ computer-driven powerhouse came off to a great start after a stellar performance in 2024. The Renaissance Institutional Diversified Alpha Fund has gained 9.05% as of February, continuing to build on its impressive 2024 return of 15.6%, which was its best since its inception in 2021. Meanwhile, the Renaissance Institutional Equities Fund has had its best start in over ten years, rising 11.85% in the first two months of 2025. Both funds are allowed to maintain sizable individual stock positions in addition to using stock index futures and options to help manage risk. However, the firm warns that it may be difficult to quickly unwind these sizable holdings without impacting market prices.
For this list, we picked stocks from Renaissance Technologies’ 13F portfolio as of the end of the fourth quarter of 2024. These equities are also popular among elite hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
Is United Therapeutics Corporation (UTHR) the Best Stock to Buy According to Jim Simons’ Renaissance Technologies?
A team of scientists in a laboratory, running tests on a biotechnology product.
Renaissance Technologies Q4 Stake: $737.2 million
Number of Hedge Fund Holders: 42
United Therapeutics Corporation (NASDAQ:UTHR) is a biotechnology company that develops and manufactures organ replacements and treatments for organ disorders. The company’s three primary medications, Tyvaso, Orenitram, and Remodulin, are targeted at patients, hospitals, and specialty pharmacies.
TD Cowen reiterated its Buy rating for United Therapeutics Corporation (NASDAQ:UTHR) on May 7, citing a stable $400 price target. The endorsement follows a recent meeting with the company’s management, which took place after their earnings call for the first quarter. TD Cowen analysts stated that management discussed the ongoing introduction of Tyvaso PH-ILD and expressed confidence in the drug’s ability to treat Idiopathic Pulmonary Fibrosis (IPF), with preliminary results anticipated in the second half of the year.
United Therapeutics Corporation (NASDAQ:UTHR) exceeded market expectations with its first quarter 2025 financial performance. The company reported earnings per share of $6.63, surpassing the projected $6.53, and achieved record revenue of $794.4 million, significantly higher than the expected $728.34 million. Strong demand across its treprostinil product lines, including Tyvaso and Remodulin, contributed to a 17% year-over-year increase in revenue.
Overall, UTHR ranks 2nd on our list of best stocks to buy according to Jim Simons’ Renaissance Technologies. While we acknowledge the potential for UTHR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than UTHR but trades at less than 5 times its earnings, check out our report about this cheapest AI stock.
Add Comment